Oculis secures FDA special protocol assessment for Phase 3 trial of optic neuritis treatment

Oculis Holding (NASDAQ:OCS) has received a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) for its Phase 3 PIONEER-1 trial.